COMMUNIQUÉS West-GlobeNewswire

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
30/04/2026
Grants OPKO a 15% equity interest in Nicoya MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an [...]
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
30/04/2026
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant [...]
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
30/04/2026
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
30/04/2026
The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
30/04/2026
Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact. Through its global access to medicines programs, Teva reached [...]
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
30/04/2026
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that data [...]
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
30/04/2026
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
A.D.A.M. Innovations Enables Pharmacogenomics for NTT Precision Medicine
30/04/2026
Supports scientific development and laboratory testing to advance pharmacogenomics deployment across Japan TOKYO, April 30, 2026 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese corporate name: Genesis Healthcare [...]
Vicarious Surgical Reports First Quarter 2026 Financial Results
30/04/2026
WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming [...]
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
30/04/2026
LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology and AI-driven solutions, [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
30/04/2026
— The new pricing structure is made available as of February for 12,67 PLN per day at pharmacies throughout Poland AMSTERDAM, April 30, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
VVT Med Announces Positive Clinical Data for ScleroSafe(R) Published in Peer-Reviewed Indian Journal of Vascular and Endovascular Surgery
30/04/2026
Prospective Study Conducted at Holy Spirit Hospital in Mumbai Reports 95% Vein Occlusion Rate at 30 VANCOUVER, BC, April 30, 2026 (GLOBE NEWSWIRE) -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer [...]
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
30/04/2026
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Precision Neuroscience™ Partners With UChicago Medicine Researchers to Advance Brain–Computer Interface Research
30/04/2026
The collaboration expands Precision's clinical research network, deepening investigation into AI-driven neural cursor control and neuroprosthetics NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience [...]
EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer
30/04/2026
, April 30, 2026 (GLOBE NEWSWIRE) -- EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer AUSTIN, Texas, April 30, 2026 - EDAP TMS SA ( [...]
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
30/04/2026
Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician interest at recent [...]
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
30/04/2026
CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced [...]
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
30/04/2026
Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at [...]
Kriya Announces Presentations at ASGCT 2026 Highlighting Advances Across Gene Therapy Platform
30/04/2026
Kriya’s integrated R&D and manufacturing platform is designed to make gene therapies accessible for more common chronic diseases ASGCT presentations reflect Kriya’s commitment to continuously optimize its platform [...]

Pages